Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave
Authors:
- Anna HertingAHAnna Herting
- Jacqueline Jahnke-TriankowskiJJJacqueline Jahnke-Triankowski
- Aenne HarbertsAHAenne Harberts
- Golda M. SchaubGSGolda M. Schaub
- Marc LütgehetmannMLMarc Lütgehetmann
- Darius F. RuetherDRDarius F. Ruether
- Lutz FischerLFLutz Fischer
- Marylyn M. AddoMAMarylyn M. Addo
- Ansgar W. LohseALAnsgar W. Lohse
- Julian Schulze Zur WieschJWJulian Schulze Zur Wiesch
- Martina SterneckMSMartina Sterneck
Open Access
Abstract
At the start of the pandemic, liver transplant recipients (LTR) were at high risk of developing severe COVID-19. Here, the outcomes of breakthrough infections in fully vaccinated LTR (n = 98) during the Omicron wave were assessed. In most patients, a mild disease course was observed, but 11 LTR (11.2%) required hospitalization for COVID-19-related complications. All patients survived. The LTR requiring hospitalization were older (67 years vs. 54 years; p < 0.001), had a higher Charlson comorbidity index (9 vs. 5; p < 0.001), and a lower anti-S RBD titer (Roche Elecsys) prior to infection (508.3 AU/mL vs. 2044 AU/mL; p = 0.03). Long-lasting symptoms for ≥4 weeks were reported by 37.5% of LTR (30/80). Risk factors in LTR included female sex (p = 0.01; Odds Ratio (OR) = 4.92 (95% confidence interval (CI) (1.5–16.5)) and dyspnea (p = 0.009; OR = 7.2 (95% CI (1.6–31.6)) during infection. Post-infection high anti-S RBD antibody levels were observed in LTR, and healthy controls (HC), while the cellular immune response, assessed by interferon-gamma release assay (EUROIMMUN), was significantly lower in LTR compared with HC (p < 0.001). In summary, in fully vaccinated LTR, SARS-CoV-2 breakthrough infections during the Omicron wave led to mild disease courses in the majority of patients and further boosted the humoral and cellular hybrid anti-SARS-CoV-2-directed immune response. While all patients survived, older and multimorbid LTR with low baseline antibody titers after vaccination still had a substantial risk for a disease course requiring hospitalization due to COVID-19-related complications.Keywords
Funding Information
- sfb1328 (project A12, DZIFTTU 01709)
- Deutsches Zentrum für Infektionsforschung (project A12, DZIFTTU 01709)
This publication has 46 references indexed in Scilit:
- Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!Journal of Hepatology, 2022
- Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseasesJournal of Hepatology, 2021
- Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipientsJournal of Hepatology, 2021
- Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipientsJournal of Hepatology, 2021
- Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant RecipientsClinical Infectious Diseases, 2021
- Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patientsJournal of Hepatology, 2021
- COVID-19 and Solid Organ Transplantation: A Review ArticleTransplantation, 2020
- Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry studyThe Lancet Gastroenterology & Hepatology, 2020
- Impact of COVID‐19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant RegistryTransplant International, 2020
- Diagnosing and Dealing with MulticollinearityWestern Journal of Nursing Research, 1990